Evoke Pharma Inc Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2012 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Evoke Pharma Inc quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2012 to Q3 2024.
  • Evoke Pharma Inc Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$1.31M, a 22.5% increase year-over-year.
  • Evoke Pharma Inc Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$6.15M, a 19.2% increase year-over-year.
  • Evoke Pharma Inc annual Net Income (Loss) Attributable to Parent for 2023 was -$7.79M, a 5.25% increase from 2022.
  • Evoke Pharma Inc annual Net Income (Loss) Attributable to Parent for 2022 was -$8.22M, a 3.68% increase from 2021.
  • Evoke Pharma Inc annual Net Income (Loss) Attributable to Parent for 2021 was -$8.54M, a 35.1% increase from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$6.15M -$1.31M +$382K +22.5% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-07
Q2 2024 -$6.53M -$1.27M +$601K +32.2% Apr 1, 2024 Jun 30, 2024 10-Q 2024-11-07
Q1 2024 -$7.13M -$1.58M +$663K +29.6% Jan 1, 2024 Mar 31, 2024 10-Q 2024-11-07
Q4 2023 -$7.79M -$1.99M -$184K -10.2% Oct 1, 2023 Dec 31, 2023 10-K/A 2024-05-14
Q3 2023 -$7.61M -$1.69M +$320K +15.9% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 -$7.93M -$1.87M +$365K +16.4% Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-07
Q1 2023 -$8.29M -$2.24M -$69.4K -3.19% Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-07
Q4 2022 -$8.22M -$1.8M -$131K -7.83% Oct 1, 2022 Dec 31, 2022 10-K/A 2024-05-14
Q3 2022 -$8.09M -$2.01M -$44.4K -2.26% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$8.05M -$2.23M +$57.3K +2.5% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-09
Q1 2022 -$8.11M -$2.17M +$432K +16.6% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-09
Q4 2021 -$8.54M -$1.67M +$596K +26.3% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-21
Q3 2021 -$9.13M -$1.97M +$160K +7.5% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-09
Q2 2021 -$9.29M -$2.29M +$4.68M +67.1% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-09
Q1 2021 -$14M -$2.61M -$815K -45.5% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-09
Q4 2020 -$13.2M -$2.27M -$850K -59.9% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-08
Q3 2020 -$12.3M -$2.13M -$501K -30.8% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 -$11.8M -$6.97M -$4.85M -230% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-10
Q1 2020 -$6.95M -$1.79M +$175K +8.9% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-10
Q4 2019 -$7.13M -$1.42M +$342K +19.4% Oct 1, 2019 Dec 31, 2019 10-K 2020-03-12
Q3 2019 -$7.47M -$1.63M -$109K -7.15% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-10
Q2 2019 -$7.36M -$2.11M +$189K +8.21% Apr 1, 2019 Jun 30, 2019 10-Q 2020-11-10
Q1 2019 -$7.55M -$1.97M +$17.5K +0.88% Jan 1, 2019 Mar 31, 2019 10-Q 2020-11-10
Q4 2018 -$7.57M -$1.76M -$1.45M -471% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-12
Q3 2018 -$6.11M -$1.52M +$3.72M +71% Jul 1, 2018 Sep 30, 2018 10-K 2020-03-12
Q2 2018 -$9.84M -$2.3M -$677K -41.7% Apr 1, 2018 Jun 30, 2018 10-K 2020-03-12
Q1 2018 -$9.16M -$1.98M +$3.07M +60.8% Jan 1, 2018 Mar 31, 2018 10-K 2020-03-12
Q4 2017 -$12.2M -$308K +$1.22M +79.8% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-06
Q3 2017 -$13.4M -$5.24M -$2.22M -73.3% Jul 1, 2017 Sep 30, 2017 10-K 2019-03-06
Q2 2017 -$11.2M -$1.63M +$1.34M +45.3% Apr 1, 2017 Jun 30, 2017 10-K 2019-03-06
Q1 2017 -$12.6M -$5.05M -$1.83M -56.6% Jan 1, 2017 Mar 31, 2017 10-K 2019-03-06
Q4 2016 -$10.7M -$1.53M +$1.1M +41.8% Oct 1, 2016 Dec 31, 2016 10-K 2018-03-07
Q3 2016 -$11.8M -$3.03M -$290K -10.6% Jul 1, 2016 Sep 30, 2016 10-K 2018-03-07
Q2 2016 -$11.6M -$2.97M +$271K +8.35% Apr 1, 2016 Jun 30, 2016 10-K 2018-03-07
Q1 2016 -$11.8M -$3.23M +$295K +8.39% Jan 1, 2016 Mar 31, 2016 10-K 2018-03-07
Q4 2015 -$12.1M -$2.62M +$296K +10.1% Oct 1, 2015 Dec 31, 2015 10-K 2017-03-15
Q3 2015 -$12.4M -$2.74M +$1.09M +28.5% Jul 1, 2015 Sep 30, 2015 10-K 2017-03-15
Q2 2015 -$13.5M -$3.24M +$306K +8.62% Apr 1, 2015 Jun 30, 2015 10-K 2017-03-15
Q1 2015 -$13.8M -$3.52M -$565K -19.1% Jan 1, 2015 Mar 31, 2015 10-K 2017-03-15
Q4 2014 -$13.2M -$2.92M -$1.3M -80.6% Oct 1, 2014 Dec 31, 2014 10-K 2016-03-10
Q3 2014 -$11.9M -$3.83M -$3.34M -687% Jul 1, 2014 Sep 30, 2014 10-K 2016-03-10
Q2 2014 -$8.61M -$3.55M -$3.31M -1379% Apr 1, 2014 Jun 30, 2014 10-K 2016-03-10
Q1 2014 -$5.3M -$2.96M -$2.46M -498% Jan 1, 2014 Mar 31, 2014 10-K 2016-03-10
Q4 2013 -$2.84M -$1.62M -$944K -140% Oct 1, 2013 Dec 31, 2013 10-K 2015-03-04
Q3 2013 -$1.89M -$486K +$350 +0.07% Jul 1, 2013 Sep 30, 2013 10-K 2015-03-04
Q2 2013 -$1.89M -$240K +$119K +33.1% Apr 1, 2013 Jun 30, 2013 10-K 2015-03-04
Q1 2013 -$2.01M -$494K +$6.17K +1.23% Jan 1, 2013 Mar 31, 2013 10-K 2015-03-04
Q4 2012 -$2.02M -$672K Oct 1, 2012 Dec 31, 2012 10-K 2014-03-25
Q3 2012 -$486K Jul 1, 2012 Sep 30, 2012 10-K 2014-03-25
Q2 2012 -$359K Apr 1, 2012 Jun 30, 2012 10-K 2014-03-25
Q1 2012 -$500K Jan 1, 2012 Mar 31, 2012 10-K 2014-03-25
* An asterisk sign (*) next to the value indicates that the value is likely invalid.